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ABSTRACT  
Objective: Type 2 Diabetes is one of the chronic diseases with a high prevalence and consequently a substantial socio-economic burden in Arab 
countries. In this paper, we evaluated the antidiabetic drugs consumption in Morocco during the period of 1991 to 2005, drug classes used and the 
effect of major studies on the consumption of the biguanides.  
Methods: We used sales data from the subsidiaries of the Intercontinental Marketing Service Health. The consumption volume was converted to 
Defined Daily Dose (DDD). 
Results: During 1991-2005 antidiabetic drugs consumption increased from 1.37 to 4.22 DDD/1000 inhabitants/day. In 2005 the sulfonylureas 
were the most consumed 2.96 DDD/1000 inhabitants/day) followed by the Biguanides (1.06 DDD/1000 inhabitants/day) and glinides 0.1 
DDD/1000inhabitants/day. The largest consumption share in volume was held by sulfonylureas 72.22%, followed by the biguanides 22.22%. 
Conclusion: This study documents progressive changes in the consumption of antidiabetic’s between 1991-2005 in Morocco. However, the 
significant increase in the utilization of antidiabetic’s drugs is not the result of increased adherence but of increased patient number, since the use of 
metformin as first line therapy was still suboptimal and influenced by different studies as the Campbell and UKPDS study.  
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INTRODUCTION  
Diabetes represents a major public health problem in Morocco as 
they do in both the industrialized and the developing countries. It is 
widely considered one of the world’s largest human health 
problems, as documented by its growing prevalence [1, 2]. In 
addition, more than 240 million people worldwide are estimated to 
have diabetes, and this is likely to pass 360 million by 2030 [3].  
The main therapeutic goals for the treatment of type 2 diabetes 
mellitus are to enhance insulin secretion and lower systemic glucose; 
an increased blood glucose level is associated with a greater risk of 
microvascular and macrovascular complications. It has been reported 
that macroangiopathy can affect up to one-third of patients diagnosed 
with type 2 diabetes [4]. Diabetic patients require multiple 
interventions to reduce their risk of microvascular and macrovascular 
complications. These complications not only diminish the health of the 
patients and may disable them but also put a high financial burden on 
the healthcare system. The United Kingdom Prospective Diabetes 
Study clearly proved the benefits of intensive glycemic control in 
patients with type 2 diabetes [5]. Previous studies have shown that 
increased adherence to oral antihyperglycemic drugs (OAHDs) results 
in better metabolic control and, consequently, in decreased 
hospitalization rates and lowered total annual healthcare costs [6, 7]. 
Moreover, a systematic review of 20 reports showed that adherence to 
OAHD therapy varied widely, ranging from 36% to 93% [8].  
In most Arab countries, including Morocco, the prevalence of diabetes 
was 6.6% and was similar for males and females [9]. The majority of 
diabetes patients are predominantly managed and treated by general 
practitioners and diabetologists. Today’s clinicians are presented with an 
extensive range of oral antidiabetic drugs for type 2 diabetes.  
The main aim of the present study was to describe trends in the use 
of antidiabetic’s medications within and across different therapeutic 
classes using nationally representative data from 1991 to 2005, and 
to have an idea about the consumed antidiabetic’s drugs and the 
effect of major studies on the consumption of biguanides.  
MATERIALS AND METHODS 
We used sales data from the Moroccan subsidiary of Intercontinental 
Marketing Service Health (IMS Health), these data are for the drugs 
sold by private pharmacists or 90% of the global pharmaceutical 
consumption in Morocco. IMS Health conducts surveys of the market 
share and the volume of sales expressed in units. The collection of the 
data is essentially made from indirect sources, monthly from the 
pharmaceutical wholesalers and from direct sources and quarterly 
from pharmacies. The study involved the main antidiabetic classes 
with their Anatomical Therapeutic Chemical system (ATC). Data from 
IMS sales in units were converted to DDDs/1000 Inhabitants per day 
(DDD/1000 Inhabitants/day = [Number of DDD/Number of days * 
Number of inhabitants]*1000), the simplest and most accessible unit 
of measurement among the different methods of measuring 
consumption of drugs [10], normalized and validated by the World 
Health Organization (WHO). This unit of measurement allows 
comparisons at the international level by eliminating the difficulties 
associated with the heterogeneity of dosage forms, presentations, and 
dosages of drugs across countries. For the calculation of the DDDs, we 
have used the values in DDD proposed by the WHO, assigned to each 
dosage form of a drug, which is “an estimate of the maintenance’s 
average dose per day for a drug used for its main indication for an 
average adult.” Thus, for each drug of the ATC, a daily dose is given the 
value of a DDD. In this study, we used the ATC system version of the 
European Pharmaceutical Market Research Association [11].  
RESULTS  
During the study period from 1991 to 2005, the total consumption of 
antidiabetic’s went from 1.37 to 4.22 DDD/1000 inhabitants/day 
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(DID), in 2005 the sulfonulyreas was the most consumed 2.96 DID 
for each one, followed by the short acting Biguanides 1.06 DID. The 
consumption of other classes of drugs namely the glinides and 
inhibitor of alpha-glucosidase witnesses a much slower evolution. 
However, there was a much slower evolution of other classes such as 
glinides glitazones as shown in (table 1). 
 
Table 1: Evolution of consumption in DID of the different families of antidiabetic drugs 
  1991 2000 2005 
DID % DID % DID % 
Sulfonylureas 1.061 77.05 2.598 80.284 2.969 61.46 
Glinides - - - - 0.102 6.25 
Glitazones - - - - 0.011 3.12 
Biguanides 0.316 22.95 0.563 17.399 1.065 22.92 
Alpha-glucosidade inhibitors - - 0.075 2.317 0.081 6.25 
∑ 1.377 100% 3.236 100% 4.229 100% 
DID: DDD/1000 Inhabitants/Day 
 
In 2005 the most consumed products were the sulfonylureas 2.96 
DID follow by biguanides 1.06 DID and the alpha-glucosidase 
inhibitors 0.08 DID. We most note that during the period of our 
study, new drugs have been introduced into the market and 
became the most widely consumed in Morrocco for 2005 as shown 
in (table 2). 
 
Table 2: Consumption trends of antidiabetic drugs in international non–proprietary name (INN) 











Gliclazide A10BB09 0.35 0.948 0.876 
Glibenclamide A10BB01 0.44 1.191 1.122 
Glipizide A10BB07 0.11 0.16 0.108 
Gliquidone A10BB08 - 0.046 0.034 
Carbutamide A10BB06 0.11 0.031 0.01 
Chlorpropamide A10BB02 0.01 0.006 0 
Tolbutamide A10BB03 0.05 0 0 
Glitazones     
Roziglitazone A10BG02 - - 0.011 
Biguanides     
Metformin A10BA02 0.31 0.563 1.065 
Alpha-glucosidase inhibitors      
Acarbose A10BF01 - 0.075  0.081  
INN: International Non–proprietary Name/ATC: Anatomical, Therapeutic and Chemical classification/DID: DDD/1000 Inhabitants/Day  
 
 
Fig. 1: Consumption trends segmentation of antidiabetic drugs in Defined Daily Dose (DDD) 
 
Similarly the number of antidiabetic commercials specialties in 
Morocco from 6 in 1991 to 16 in 2005. In 1991 antidiabetic 
consumption, in DDD was represented by the sulfonylureas 72.22%, 
biguanides 22.22%, glinides 2.22% and inhibitor of alpha-
glucosidase 2.22%, but in 2005, it was 71.77% for the sulfonylureas, 
25.38 for biguanides, 1.72% for the inhibitor of alpha-glucosidase 
and 1.15% for glinides as shown in (fig. 1). 
The evolution of the consumption of oral antidiabetic drugs during 
this period of study is influenced by major studies on prescribing 
the drug and publishing the results of these randomized studies 
have involved oral medications in evaluating their influence on 
consumption of metformin compared with other oral antidiabetic 
agents. We will mention the most important for the most 
prescribed families. 
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Fig. 2: Effect of studies on the consumption of metformin in defined daily dose (DDD) 
 
The increase in the number of DDD of metformin during this period 
was influenced by the results of UKPDS and Campbell study from 
1995 to 1998 as shown in (fig. 2). 
DISCUSSION 
The diabetes management includes many areas that may be 
influenced by the patient severity. Moreover, the antidiabetic drug 
market is characterized by a number of new drugs that have been 
introduced during the period of this study, but this the first study 
that analyzes antidiabetic drugs consumption in Morocco. From 
1999 to 2005, the consumption of antidiabetic drugs during this 
period has significantly increased in Morocco, with a predominance 
of sulfonylureas and biguanides but small change for other drugs 
families. The consumption’s evolution for these two families of 
antidiabetic’s drugs reflects that the sulfonylureas and metformin 
are two different pathophysiological target mechanisms underlying 
the type 2 diabetes. And this increase in the utilization of these 
families can be explained by the similar scale increase in the number 
of patients treated. The comparison of the uses of oral antidiabetic 
show an opposition between Morocco and these European countries 
that is distinguished by a larger range of new antidiabetics and 
therefore more expensive, and with a more targeted dissemination 
of this drugs. The Consumption levels of oral antidiabetic agents in 
European countries are close to the prevalence of the disease 
assessed in these countries. In contrast, the United Kingdom 
consumption is much lower than one observed in France with 
similar prevalence. In Spain, it is 1.4 times higher than that the one 
noted in France in 2004, with 2.3 times higher prevalence [12]. 
However, this analysis is partial because we do not have any 
information on the habits of diabetes care in each country 
(monotherapy or combination therapy.). 
Consumption analysis of oral antidiabetic agents in the period of this 
study showed that the increase in the number of DID was high even, 
in 2005 it was 4.22 DID in over 50% represented by sulfonylureas 
despite the observed break 2002. This increase reflects better 
detection and management of diabetes, but these numbers are still 
relatively small compared to the number recorded in France, which 
was 39.8 for 2004 against 4.09 for the same year in Morocco. In 
terms of distribution of antidiabetic’s drugs, Morocco has an atypical 
profile, unlike other European countries. France, Germany and the 
United Kingdom represented the family of biguanides metformin 
ranked first in terms of consumption with a number of DID for 
France that was 20.88, 21.38 for Germany and 20.12 for the United 
Kingdom [12]. In fact, in Morocco, the consumption of antidiabetic 
agents increased and this is due to the increase in the prevalence of 
type 2 diabetes. Metformin during this period occupied the 2nd place 
after sulfonylureas because of its pharmacological properties, 
including the fact that many studies have shown the benefit of this 
molecule alone or in combination in glycemic control in non-insulin 
dependent diabetic patients. Its efficiency is comparable to that of 
insulin and sulfonylureas. It also improves the lipid profile and 
decreases the incidence of micro-and macrovascular complications. 
Moreover, since the study of the United Kingdom Prospective 
Diabetes Study, metformin has become the reference drug in the 
treatment of obese diabetic [13, 14]. However, in this period there 
was a high increase in the use of metformin either as monotherapy 
or with other drugs. This rise was partially due to the increased use 
of metformin as initial treatment. These findings are consistent with 
previous reports [15]. However, the percentage of patients who 
started oral antidiabetic treatment with metformin in 2004 is still 
low in comparison with other countries [16]. Although the use of 
antidiabetic’s drugs had an increase during the study period, the 
consumption of other families remained marginal such as alpha-
glucosidase inhibitors, Glinides and Glitazones. The management of 
diabetes is based on appropriate long-term lifestyle measures, 
including getting enough exercise, correcting major dietary errors, 
taking prescribed drugs regularly and treating all associated 
cardiovascular risk factors. Between 1991 and 2005, the 
consumption of metformin evolved considerably, during this period 
the increase to use of metformin influenced by the different study as 
the study of Campbell and UKPDS study [14, 17]. 
CONCLUSION 
In Morocco antidiabetic’s consumption has increased between 
1991 and 2005, the most frequently antidiabetic prescribed were 
the sulfonylureas followed by biguanides and glinides, increasing 
the consumption of the biguanide family in this period was 
influenced by two major studies UKPDS and Campbell. Despite the 
increase of these drugs consumption, this level remains very low 
for the needs of diabetics’ patients. The interpretation of the 
current results findings also highlights the need for other studies 
epidemiological, prescribing patterns, management protocols, 
access to care.  
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